Insys Therapeutics (INSY) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Piper Jaffray Cuts Price Target as Insys Therapeutics' (INSY) Guides to a Decline in Subsys Sales
February 24, 2016 10:20 AM ESTPiper Jaffray maintained an Overweight rating on INSYS Therapeutics (NASDAQ: INSY), and cut the price target to $46.00 (from $49.00), following the company's 4Q earnings report. Insys reported adjusted diluted EPS of $0.36 on revenues of $91M, in-line with Street estimates. INSY is guiding to a sequential decline in Subsys sales in 1Q16, driven in significant part by the company no longer contracting with OptumRx. This is... More
